Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | BX-912 | 1 | 72 | 1.0 | 5114.5 | 11641.0 | 1742.8 | 0.0 | 0.481 | 0.439 | 2.740 | HCC1806 BX912 0 1 72 |
| HCC1806 | BX-912 | 1 | 72 | 3.2 | 2492.8 | 11641.0 | 1742.8 | 0.505 | 0.140 | 0.214 | 2.740 | HCC1806 BX912 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 0.001 | 10768.8 | 11894.0 | 1742.8 | -3.0 | 0.930 | 0.905 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 0.0032 | 10690.3 | 11894.0 | 1742.8 | -2.49 | 0.924 | 0.899 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 0.01 | 10822.0 | 11894.0 | 1742.8 | -2.0 | 0.933 | 0.910 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 0.032 | 11055.0 | 11894.0 | 1742.8 | -1.49 | 0.948 | 0.929 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 0.1 | 11102.8 | 11894.0 | 1742.8 | -1.0 | 0.951 | 0.933 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 0.32 | 11152.3 | 11894.0 | 1742.8 | -0.495 | 0.954 | 0.938 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 1.0 | 11213.0 | 11894.0 | 1742.8 | 0.0 | 0.958 | 0.943 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | Alpelisib | 1 | 72 | 3.2 | 10596.3 | 11894.0 | 1742.8 | 0.505 | 0.918 | 0.891 | 2.771 | HCC1806 BYL719 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 0.001 | 11230.8 | 11282.8 | 1742.8 | -3.0 | 0.997 | 0.995 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 0.0032 | 11273.8 | 11282.8 | 1742.8 | -2.49 | 0.999 | 0.999 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 0.01 | 11404.3 | 11282.8 | 1742.8 | -2.0 | 1.010 | 1.010 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 0.032 | 11305.3 | 11282.8 | 1742.8 | -1.49 | 1.000 | 1.000 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 0.1 | 11409.3 | 11282.8 | 1742.8 | -1.0 | 1.010 | 1.010 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 0.32 | 11440.8 | 11282.8 | 1742.8 | -0.495 | 1.010 | 1.010 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 1.0 | 11624.3 | 11282.8 | 1742.8 | 0.0 | 1.020 | 1.030 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | CAL-101 | 1 | 72 | 3.2 | 11994.0 | 11282.8 | 1742.8 | 0.505 | 1.050 | 1.060 | 2.695 | HCC1806 CAL101 0 1 72 |
| HCC1806 | Everolimus | 1 | 72 | 0.001 | 10053.0 | 12020.5 | 1742.8 | -3.0 | 0.876 | 0.836 | 2.786 | HCC1806 Everolimus 0 1 72 |
| HCC1806 | Everolimus | 1 | 72 | 0.0032 | 9348.8 | 12020.5 | 1742.8 | -2.49 | 0.827 | 0.778 | 2.786 | HCC1806 Everolimus 0 1 72 |
| HCC1806 | Everolimus | 1 | 72 | 0.01 | 9417.5 | 12020.5 | 1742.8 | -2.0 | 0.832 | 0.783 | 2.786 | HCC1806 Everolimus 0 1 72 |
| HCC1806 | Everolimus | 1 | 72 | 0.032 | 9329.3 | 12020.5 | 1742.8 | -1.49 | 0.826 | 0.776 | 2.786 | HCC1806 Everolimus 0 1 72 |
| HCC1806 | Everolimus | 1 | 72 | 0.1 | 9054.3 | 12020.5 | 1742.8 | -1.0 | 0.807 | 0.753 | 2.786 | HCC1806 Everolimus 0 1 72 |
| HCC1806 | Everolimus | 1 | 72 | 0.32 | 9042.0 | 12020.5 | 1742.8 | -0.495 | 0.806 | 0.752 | 2.786 | HCC1806 Everolimus 0 1 72 |
| HCC1806 | Everolimus | 1 | 72 | 1.0 | 8742.8 | 12020.5 | 1742.8 | 0.0 | 0.784 | 0.727 | 2.786 | HCC1806 Everolimus 0 1 72 |